Targeted Metabolomics Panels & Single Analyte Assays

Our readily available or custom-developed quantitative panels help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted panels and single analyte assays cover >1000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.

• Informing the Entire Drug Discovery & Development Cycle
  Targeted panels are valuable for rapidly and accurately establishing pharmacodynamics, fueling translational studies, gauging efficacy and safety, and informing post-market surveillance studies.With several matrices supported, you can gain more profound insights from various applications, including microbiome research and bioprocessing.
• Biomarker Development & Validation
  From discovery to commercialization, improve biological understanding by tracking biomarkers with targeted metabolite panels.The role of biomarkers is expanding to inform new indications and targets, patient segmentation and novel mechanisms of action. According to the context of use of your biomarkers, Metabolon can guide you to ensure study integrity and high-quality data generation in compliance with regulatory standards.
• Revealing Microbiome Function
  Build upon the system-wide view of Metabolon’s global metabolomics with additional insights from a series of microbiome-focused targeted panels. Measure the effects of microbiome-related analytes with absolute quantitation for the most precise and systematic view of microbiome-related activity.
• Custom Assay Development
  If one of our existing targeted panels doesn’t meet your needs, our experienced team of scientists can create a custom panel specifically for your area of interest. We have developed hundreds of customized panels representing >1,000 metabolites from all areas of the metabolome with multiplexing support. All of our assays are validated for Research use only (RUO) or Good Clinical Practice (GCP)/ Good Clinical Laboratory Practice (GCLP) and Clinical Laboratory Improvement Amendments (CLIA).

Targeted assays are an ideal follow-up to the global screening of hundreds to thousands of metabolites with our revolutionary Precision Metabolomics™ technology. Following the identification of candidate biomarkers, you can select pre-developed assays from an ever-expanding set of >1,000 metabolites and lipids or initiate the development of a custom assay. Assays can inform a research or clinical trial setting.

Guide Your Biomarker Development with Expert Consultation

Each project begins with a scientist-to-scientist consultation to determine your assay needs, including regulatory requirements and project timeline. In doing so, we explore how to best meet those needs through existing assays, custom-developed assays, or a combination of both.

In-depth institutional knowledge of metabolic pathways, along with our deep expertise in metabolite-based mass spectrometry, guides the selection of candidate biomarkers. The focus is on ensuring that the critical aspects of the subsequent study or trial are clearly defined and that the assays and multiplexing scheme most effectively meet your needs.

Assays can be customized based on your needs and developed and validated for RUO or run under GCP/GCLP.. Our expertise throughout the continuum of biomarker development makes Metabolon an exceptional partner for validated assay development and analysis.

Global Discovery Panel

5,400+ metabolites

70 major pathways

Targeted Panels & Single Analyte Assays

1,000 individual lipid species

• Our unique platform provides single point quantitation of 14 lipid classes, including principal phospholipid, sphingolipid, and neutral lipid classes.

450+ metabolites covered by ready-to-use absolute quantification assays

• Fit-For-Purpose Biomarker Validation.
• Capability to adhere to Good Clinical Practice (GCP)/ Good Clinical Laboratory Practice (GCLP) standards.
• Extensive Method Validation according to FDA Bioanalytical Method Validation Guidance, 2018 or EMA Guideline on Bioanalytical Method Validation, 2011.
• Capability to develop/validate methods and perform diagnostic testing on human samples according to regulations certified by Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP) for diagnostic testing on human samples.

Our Expertise

200+ patents
3,500+ publications
10,000+ studies

• Amino Acids
• Bile Acids
• Central Carbons
• Complex Lipids
• Fatty Acids Metabolism
• Free Fatty Acids
• Impaired Glucose Tolerance
• Indoles/Uremic Toxicity
• Insulin Resistance
• Metal Analysis
• Oxysterols
• Sebum
• Short Chain Fatty Acids (SCFA)
• Tryptophan/Kynurenine

Single Analyte Assays

• Beta-Hydroxybutyrate
• C4
• Creatinine
• Salivary Glucose